Case report

A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure

Shotaro Ito, Hajime Asahina, Naoko Yamaguchi, Utano Tomaru, Tadashi Hasegawa, Yutaka Hatanaka, Kanako C. Hatanaka, Hiroshi Taguchi, Taisuke Harada, Hiroshi Ohira, Daisuke Ikeda, Hidenori Mizugaki, Eiki Kikuchi, Juno Kikuchi, Jun Sakakibara-Konishi, Naofumi Shinagawa, Satoshi Konno

SMARCA4-deficient thoracic sarcomatoid tumors were characterized by inactivating mutations of SMARCA4 and often found in the chest of young and middle-aged males with a smoking history. Recently, SMARCA4-deficient thoracic sarcomatoid tumors were reported to represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. The main complication of this tumor is compression of the respiratory tract and/or blood vessels. A 39-year-old man presented with a 2-month history of fever and dyspnea. Computed tomography revealed a mediastinal tumor invading the right and left pulmonary arteries. Because of severe right heart failure, we considered him ineligible for bronchoscopy. We scheduled palliative irradiation with 40 Gy/20 Fr to improve hemodynamics and perform endobronchial ultrasound transbronchial needle aspiration later. However, irradiation was ineffective, and his general condition deteriorated quickly and he died after a 7-week hospitalization. An autopsy revealed that the diagnosis was SMARCA4-deficient thoracic undifferentiated carcinoma. It has been reported that this tumor is insensitive to radiotherapy and there were some cases which responded to an immune checkpoint inhibitor. Therefore, when caring for patients with mediastinal tumors that invade and compress the trachea and large vessels, it is important to consider this tumor as a differential diagnosis and try to make a pathological diagnosis as soon as possible.

1. Introduction

SMARCA4 is a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex [1]. It plays an important role in chromatin remodeling and, thus, in the regulation of vital cellular processes and functions, such as proliferation and differentiation [2]. SMARCA4-deficient thoracic sarcomatoid tumors (SD-TSTs) are characterized by inactivating mutations of SMARCA4 and are often found in the chest of young and middle-aged males with a smoking history [3,4]. The neoplasms are mainly located in the mediastium, followed by the pleura and lungs. The main complication of SD-TSTs is compression of the respiratory tract and/or blood vessels [5]. Recently, Rekhtman et al. reported that SD-TSTs primarily represented smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic
The initial choice of therapy for invasive tumors is critical as failure is likely to deteriorate the patient’s general condition, with the only subsequent option being palliative care. Herein, we report a case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma (SMARCA4-DTC) with severe pulmonary artery invasion.

2. Case presentation

A 39-year-old man presented at the outpatient clinic of a community hospital with a 2-month history of fever and dyspnea and no relevant past history. He had a smoking history of 19-pack-years. Cardiomegaly was seen on the chest radiograph. Right ventricular enlargement and flattening of the interventricular septum of the left ventricle with pericardial effusion (Fig. 1A–B) were seen on echocardiography. Computed tomography (CT) revealed a mediastinal tumor invading the right and left pulmonary arteries (Fig. 2A–D). Pulmonary angiography showed severe pulmonary artery stenosis (Fig. 1C–D).

He was then referred to our department for further management. Due to severe right heart failure, his Eastern Cooperative Oncology Group performance status (ECOG PS) was 3, and he could not lie on his back for more than 30 minutes despite the use of morphine and catecholamine. Therefore, bronchoscopy could not be performed. We scheduled palliative irradiation with 40 Gy/20 Fr to improve the hemodynamics and perform Endobronchial ultrasound transbronchial needle aspiration later. However, irradiation was ineffective, and his general condition deteriorated. He died after a 7-week hospitalization. An autopsy was performed after obtaining informed consent from the patient’s family. All procedures were in accordance with the Declaration of Helsinki. The tumor was a poorly differentiated carcinoma with a partial glandular structure. Immunohistochemical staining revealed that the tumor cells were positive for SMARCA2 and negative for SMARCA4. The final diagnosis was SMARCA4-DTC (Fig. 3A–D). Programmed death-ligand 1 (PD-L1) expression was observed in 1% of the tumor cells. Molecular analysis using QIAGEN comprehensive panel detected no SMARCA4 mutation, a reduced SMARCA4 copy number to 1, and loss of SMARCA4 heterozygosity.

3. Discussion

The stepwise inactivation of SMARCA2 from preexisting SMARCA4-deficient carcinomatous elements might cause SD-TSTs [6]. In our patient, the tumor cells lacked typical rhabdoid-like features and were SMARCA2-positive, leading to the final diagnosis of SMARCA4-DTC. The clinical characteristics and radio-insensitivity were consistent with SD-TSTs [5]. Recently, correlations between response to immune checkpoint inhibitors (ICIs) and loss of the SWI/SNF complex have been reported [7]. A patient with a previously SMARCA4-deficient thoracic carcinoma (SMARCA4-DTC) with severe pulmonary artery invasion.

![Fig. 1.](image1.png)
![Fig. 2.](image2.png)
Therefore, if the ECOG PS of the patient is equal to or more than 2, ICIIs might be a potentially effective treatment option.

The differential diagnoses of mediastinal tumors include radiosensitive tumors like malignant lymphomas and germ cell tumors. Therefore, it is important to know the imaging features of SMARCA4-DTC. Calcification and cystic component are usually not seen with SMARCA4-DTC. Unlike germ cell tumors, SMARCA4-DTCs are heterogeneous on post-contrast computed tomography. Compared to malignant lymphoma, which is a radiosensitive tumor, SMARCA4-DTC has a higher probability of causing vascular encasement [10–12]. In patients like ours, invasion and compression of the large vessels or the trachea by mediastinal tumors could be indicative of tumor stiffness, and SMARCA4-DTC should be considered [10].

4. Conclusion

When mediastinal tumors without calcification and cystic component invade and compress large vessels or the trachea aggressively, SMARCA4-DTC should be considered as a differential diagnosis, and biops should be attempted. Palliative irradiation before the pathological diagnosis is an important therapeutic strategy but might be ineffective. If the tumor is insensitive to palliative irradiation and the ECOG PS of the patient is ≤ 2 after the pathological diagnosis, treatment with ICI may be considered as an option. Overall, it is important to make a pathological diagnosis as soon as possible when there is a possibility of SMARCA4-DTC.

Acknowledgments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

R. Ito et al.

Declaration of competing interest

Authors declare that they have no conflict of interest.

References

[1] C.W. Roberts, S.H. Orkin, The SWI/SNF complex–chromatin and cancer, Nat. Rev. Canc. 4 (2) (2004) 153–142, https://doi.org/10.1038/nrc1273.

[2] B.G. Wilson, C.W. Roberts, SWI/SNF nucleosome remodelers and cancer, Nat. Rev. Canc. 11 (7) (2011) 481–492, https://doi.org/10.1038/nrcc3068.

[3] F. Le Léorat, S. Watson, G. Pierron, V.T. de Montpreville, J. Masliah-Planchon, M. Devouassoux-Shisheboran, G. Zalcman, Y. Allary, F. Bourdeaut, F. Thivolet-Beji, D. Broucarme-Vince, N. Girard, S. Lantuejoul, F. Galateau-Sallé, J.M. Coindre, A. Leary, O. Delattre, J.Y. Blay, F. Tirode, SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas, Nat. Genet. 47 (10) (2015) 1200–1205, https://doi.org/10.1038/ng.3399.

[4] A. Yoshida, E. Kobayashi, T. Kubo, M. Kodaira, T. Motoi, K. Yoneomori, Y. Ohe, S.I. Watanabe, A. Kawai, T. Kohno, H. Kishimoto, H. Ichikawa, N. Hirooki, Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities, Mod. Pathol. 30 (6) (2017) 797–809, https://doi.org/10.1038/modpathol.2017.11.

[5] B. Perret, L. Chalabreysse, S. Watson, J. Serre, S. Garcia, F. Forest, V. Vovelle, D. Pissaloux, V. Thomas de Montpreville, J. Masliah-Planchon, S. Lantuejoul, M. Brevet, J.Y. Blay, J.M. Coindre, F. Tirode, F. Le Léorat, SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses, Am. J. Surg. Pathol. 43 (4) (2019) 455–465, https://doi.org/10.1097/PAS.0000000000001188.

[6] N. Rekhtman, J. Montealejo, J.C. Chang, D. Alex, R.N. Punshkin, N. Al, J.L. Sauter, B. Kezaalari, A. Jungbluth, P. Desmeules, A. Beras, J.A. Bishop, J.A. Plodziewski, M.M. Gounder, A.J. Schoenfeld, A. Namakydoust, B.T. Li, C.M. Rudin, G.J. Riely, D. R. Jones, M. Ladanyi, W.D. Travis, SMARCA4-Deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas, J. Thorac. Oncol. 15 (2) (2020) 231–247, https://doi.org/10.1016/j.jtho.2019.10.025.

[7] D. Miao, C.A. Margolis, W. Gao, M.H. Voss, W. Li, D.J. Martini, C. Norton, D. Bossé, S.M. Wankowicz, D. Cullen, C. Horak, M. Wind-Rotolo, A. Tracy, M. Giannakis, F. Hodi, C.G. Drake, M.W. Ball, M.E. Allaf, A. Snyder, M.D. Hellmann, T. Ho, R. J. Motzer, S. Signoretti, W.G. Kaelin Jr., T.K. Choueiri, E.M. Van Allen, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science 359 (6377) (2018) 801–806, https://doi.org/10.1126/science.aan9591.

[8] C. Henon, J.Y. Blay, C. Massard, O. Mir, R. Bahleda, A. Le Cesne, Long lasting major response to pembrolizumab in a thoracic malignant rhadoid-like SMARCA4-deficient tumor, Ann. Oncol. 30 (8) (2019) 1401–1403, https://doi.org/10.1093/annonc/mdz160.

[9] G. Middleton, K. Brock, J. Savage, R. Mant, V. Summers, J. Connibear, R. Shah, C. Ottenemeyer, P. Shaw, S.M. Lee, S. Popat, C. Barrie, G. Barone, L. Billingha, Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial, Lancet Respir. Med. 8 (9) (2020) 895–904, https://doi.org/10.1016/s2213-2600(20)30013-3.
[10] A. Crombe, N. Alberti, N. Villard, F. Pilleul, X. Buy, F. Le Loarer, M. Kind, Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients, Eur. Radiol. 29 (9) (2019) 4730–4741, https://doi.org/10.1007/s00330-019-06017-x.

[11] L. Gu, L. Zhang, N. Hou, M. Li, W. Shen, X. Xie, Y. Teng, Clinical and radiographic characterization of primary seminomas and nonseminomatous germ cell tumors, Niger. J. Clin. Pract. 22 (3) (2019) 342–349.

[12] U. Tateishi, N.L. Müller, T. Johkoh, Y. Onishi, Y. Arai, M. Satake, Y. Matsuno, K. Tobinai, Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT, J. Comput. Assist. Tomogr. 28 (6) (2004) 782–789, https://doi.org/10.1097/00004728-200411000-00009.